Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ST316 in Familial Adenomatous Polyposis (FAP)
NCT07729371Phase 1Not yet recruiting
- Sponsor
- Sapience Therapeutics, Inc.
- Start
- Jan 2027
- Primary completion
- Dec 2028
01
Overview
Phase 1, open-label trial of ST316 in familial adenomatous polyposis (FAP) (3 cohorts), sponsored by Sapience Therapeutics, Inc. Primary endpoints: Incidence of Treatment Related Adverse Events and Percentage change from Baseline in Colorectal/ Pouch Poly Burden at Month 6. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
ST316
03
Conditions
familial adenomatous polyposis (FAP)
Beyond the preview
Go deeper on NCT07729371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07729371.